What was known before {#section21-2054358117703071}
=====================

Indigenous people living in Canada have rates of kidney disease that are 3 times higher than the non-Indigenous Canadian population, yet no studies have specifically examined patterns of kidney disease among Métis citizens living in Ontario.

What this adds {#section22-2054358117703071}
==============

The risk of kidney disease may be similar or slightly higher among Métis citizens of Ontario compared with the general population matched on age, sex, and area of residence.

Background {#section23-2054358117703071}
==========

Indigenous peoples living in Canada have rates of kidney disease that are 3 times higher than non-Indigenous Canadians.^[@bibr1-2054358117703071]^ The reasons for this are complex and multifactorial, but may include a genetic predisposition^[@bibr2-2054358117703071]^ and limited access to culturally appropriate primary health care.^[@bibr1-2054358117703071]^ As well, a history of disadvantage in Canadian society may have contributed to a higher prevalence of low birth weight, which is associated with reduced nephron endowment,^[@bibr3-2054358117703071][@bibr4-2054358117703071]-[@bibr5-2054358117703071]^ postinfectious glomerulonephritis,^[@bibr6-2054358117703071],[@bibr7-2054358117703071]^ obesity, early-onset diabetes, and increased vascular disease.^[@bibr1-2054358117703071]^

Métis people are a unique Indigenous community with their own values, beliefs, traditions, culture, language, territory, and history. There are approximately 86 000 Métis people living in Ontario, which comprise about 30% of the total Indigenous population in Canada.^[@bibr8-2054358117703071]^ The Métis are the fastest growing Indigenous population in Canada.^[@bibr9-2054358117703071]^ Historically, Métis people are descendants of Aboriginal women and European men. To our knowledge, no prior reports have examined the patterns of kidney disease among Métis people residing in Canada. At the request of the Métis Nation of Ontario (MNO), we developed a research partnership to examine kidney disease and related outcomes in this unique population. Our objective was to compare the prevalence of chronic kidney disease, the incidence of acute kidney injury, and end-stage kidney disease among registered Métis citizens of Ontario with the general Ontario population matched on age, sex, and geographic area of residence. We also examined 1-year outcomes among those hospitalized with acute kidney injury.

Methods {#section24-2054358117703071}
=======

Design and Setting {#section25-2054358117703071}
------------------

Ontario has a population of 13 million individuals with universal health care covering both emergency and preventive care. The MNO is a Métis-specific governance body that was established in 1993 to represent Métis citizens and communities in Ontario. The MNO maintains a citizenship registry which currently captures approximately 18 000 individuals or 20% of the provincial Métis population. To apply as a citizen, one must meet the Métis National Council's National Definition for Citizenship within the Métis Nation: "Métis means a person who self-identifies as Métis, is distinct from other Aboriginal peoples, is of historic Métis Nation ancestry, and is accepted by the Métis Nation."^[@bibr10-2054358117703071]^

We conducted a retrospective, population-based cohort study using the MNO citizenship registry, current as of 2009, which we linked to Ontario's administrative data held at the Institute for Clinical Evaluative Sciences (ICES). This research was commissioned by the MNO and was conducted through the provincial ICES Kidney, Dialysis and Transplantation Research Program. This research uses the recommended policies for the ethical conduct of research involving Indigenous peoples.^[@bibr11-2054358117703071]^ It is offered in a spirit of respect. Data sets were linked using unique encoded identifiers and analyzed at ICES Western, London, Ontario, Canada. This study was pre-approved by the institutional review board at Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. The reporting of this study follows the checklist of recommendations for reporting of observational studies using the REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement (see [Appendix A](#app1-2054358117703071){ref-type="app"}).^[@bibr12-2054358117703071]^

Data Sources {#section26-2054358117703071}
------------

We used the MNO citizenship registry to create a cohort of registered Métis citizens in Ontario who were alive as of April 1, 2003. We used 7 other linked databases held at ICES to examine study outcomes during follow-up (April 1, 2003, to March 31, 2012). The Canadian Institute for Health Information (CIHI) Discharge Abstract Database and the National Ambulatory Care Reporting System Database contain diagnostic and procedural information for all hospital admissions and emergency department visits in Ontario. The Ontario Health Insurance Plan (OHIP) Claims Database captures physician billing claims for inpatient, outpatient, and laboratory services rendered to all persons in Ontario. The Registered Persons Database includes birth, death, and demographic information for all Ontario residents. The Ontario portion of the Canadian Organ Replacement Register (CORR) contains information on all organ transplantation types and dialysis. We also linked laboratory data from 2 sources to obtain kidney function laboratory test results (serum creatinine) for our cohort. The Dynacare Database includes outpatient laboratory tests for a large commercial lab provider with locations across Ontario. Twelve hospitals in Southwestern Ontario share a common electronic medical record (Cerner, Missouri, USA) which contains inpatient, emergency department, and outpatient laboratory testing.

Cohort Selection {#section27-2054358117703071}
----------------

We performed initial data cleaning to exclude individuals with invalid identifiers or with missing date of birth or sex ([Figure 1](#fig1-2054358117703071){ref-type="fig"}). We also excluded non-Ontario residents, individuals who were younger than 18 years as of April 1, 2003, and patients with previous end-stage kidney disease (defined as chronic dialysis 1 year before April 1, 2003, or a kidney transplant in the 5-year period before April 1, 2003). To assess the incidence of acute kidney injury during follow-up, we further excluded patients with evidence of pre-existing chronic kidney disease (defined as 1 or more codes for chronic kidney disease in the year before April 1, 2003; codes provided in [Appendix B](#app2-2054358117703071){ref-type="app"}).

![Flow diagram of cohort build.\
*Note.* MNO = Métis Nation of Ontario; AKI = Acute Kidney Injury.](10.1177_2054358117703071-fig1){#fig1-2054358117703071}

We matched eligible Métis citizens to individuals from the general Ontario population, using a 1-to-4 ratio, on age (±2 years), sex, census dissemination area (a proxy for geographical location of residence describing populations of 400 to 700 individuals), and evidence of a baseline outpatient serum creatinine measurement in the year prior to April 1, 2003. To avoid overmatching, we did not match on diabetes or other comorbidities because these conditions may be a mechanism of kidney disease in some individuals. Hereafter, the matched sample from the general Ontario population is referred to as the general population.

Measures and Outcomes {#section28-2054358117703071}
---------------------

### Baseline characteristics {#section29-2054358117703071}

We measured the following demographic characteristics in both cohorts: sex, income quintile, geographic location, and age. We also gathered baseline information on health care use in the year before April 1, 2003 (nephrologist visits, primary care visits, and hospitalizations), and presence of comorbidities in the 5 years before April 1, 2003 (diabetes, myocardial infarction and stroke).

### Chronic kidney disease {#section30-2054358117703071}

We defined the prevalence of chronic kidney disease in 2 ways: (1) point prevalence at baseline estimated using outpatient serum creatinine in the year before April 1, 2003, and (2) period prevalence during follow-up (April 1, 2003, to March 31, 2012) using diagnostic codes. Prevalence at baseline was estimated by looking for at least one serum creatinine value in the previous year (if a person had multiple tests, then we used the most recent value). Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation.^[@bibr13-2054358117703071]^ This calculation assumed no individuals were of black race because we lacked data on this variable; however, less than 5% of Ontarians are black.^[@bibr9-2054358117703071]^ Severity of chronic kidney disease was defined as mild (60 \> eGFR ≥ 45mL/min/1.73 m^2^) or moderate to severe (eGFR \< 45mL/min/1.73 m^2^). Given the low number of patients with albuminuria measurements in our data sets, we did not use albumin-to-creatinine ratios to define chronic kidney disease.

The prevalence of chronic kidney disease during follow-up was estimated based on the presence of at least one validated administrative diagnostic code (codes provided in [Appendix B](#app2-2054358117703071){ref-type="app"}).^[@bibr14-2054358117703071]^ We originally planned to assess outcomes for chronic kidney disease, including end-stage kidney disease; however, event rates were too small to report.

### Acute kidney injury {#section31-2054358117703071}

The incidence of acute kidney injury during follow-up was estimated after excluding those with one or more codes for chronic kidney disease in the year before April 1, 2003. Acute kidney injury was defined in 2 ways: (1) a rise in serum creatinine \>50% or \>27 µmol/L from an outpatient baseline value^[@bibr15-2054358117703071]^ and (2) the presence of a diagnostic code in hospital for acute kidney injury. For the first definition, we identified all patients with a serum creatinine value measured during follow-up (either in the emergency department or as an inpatient); we then selected the highest creatinine value and compared this with the most recent value taken during the year before April 1, 2003.

For the second definition, we defined acute kidney injury using validated administrative diagnostic codes in hospital ([Appendix B](#app2-2054358117703071){ref-type="app"}).^[@bibr16-2054358117703071]^

#### One-year outcomes after acute kidney injury {#section32-2054358117703071}

Among patients with acute kidney injury defined using diagnostic codes, we examined the following outcomes (up to March 31, 2013): (1) duration of hospital stay, (2) death during hospitalization, (3) short-term dialysis during hospitalization, (4) death within 1 year of hospital discharge, and (5) non-recovery of kidney function requiring chronic dialysis within 1 year of hospital discharge. The codes used to define these outcomes are provided in [Appendix B](#app2-2054358117703071){ref-type="app"}.

### End-stage kidney disease {#section33-2054358117703071}

We defined the incidence of end-stage kidney disease as evidence of at least 1 treatment code for chronic dialysis or kidney transplantation (codes in [Appendix B](#app2-2054358117703071){ref-type="app"}) during follow-up (April 1, 2003 to March 31, 2012).

Statistical Analysis {#section34-2054358117703071}
--------------------

We compared baseline characteristics between Métis citizens and the general population using standardized differences.^[@bibr17-2054358117703071]^ The incidence of study outcomes (acute kidney injury and end-stage kidney disease) were calculated as time to first event between April 1, 2003, and March 31, 2012. The prevalence of chronic kidney disease was defined by the presence of at least one code between April 1, 2003, and March 31, 2012. The risk of incident acute kidney injury and end-stage kidney disease for Métis citizens relative to the general population was assessed using Cox proportional hazards regression, stratified on the matched sets. The risk of prevalent chronic kidney disease was assessed using a modified Poisson regression, accounting for matched sets. In a secondary analysis, binary outcomes in follow-up after an in-hospital acute kidney injury episode were evaluated using chi-square tests. For these secondary outcomes, the matched nature of the data was not accounted for, as the low number of acute kidney injury hospitalizations did not permit matched analyses in this subset of individuals. The length of stay of the hospitalization with acute kidney injury was compared between the Métis citizens and general population groups using Wilcoxon signed-rank test. All analyses were conducted using SAS Version 9.3 (SAS Institute, Cary, NC). In all analyses, we interpreted 2-tailed *P* values less than 0.05 as statistically significant.

Results {#section35-2054358117703071}
=======

A flow diagram of the cohort selection is shown in [Figure 1](#fig1-2054358117703071){ref-type="fig"}. As of April 1, 2003, there were 14 021 Métis citizens in the MNO registry. After applying exclusion criteria, a total of 12 229 registered Métis citizens were successfully matched to 48 916 adults from the general population. Individuals were followed for a median of 9.0 years (interquartile range \[IQR\], 9.0-9.0). Reasons for ending the observation time included death (4.0% overall; 3.7% Métis and 4.1% general population), emigration (6.0% overall; 4.2% Métis and 6.5% general population), kidney transplant (0.4% overall; 0.4% Métis and 0.4% general population), and reaching the study accrual end date of March 31, 2012 (88.5% overall; 90.7% Métis and 88.0% general population). The total observation time was 521 700 person-years (105 595 Métis and 416 105 general population).

Baseline characteristics are shown in [Table 1](#table1-2054358117703071){ref-type="table"}. As a result of matching, most baseline characteristics were similar between groups. In both groups, the median age was 41 years (IQR, 30-51), 46% were female, and a similar proportion resided in each of the 14 Local Health Integration Networks in Ontario. However, compared with the general population, Métis citizens had a higher number of primary care visits in the year preceding cohort entry (median 3 \[IQR, 1-6\] vs 2 \[IQR, 0-5\]).

###### 

Baseline Characteristics of Individuals in the Métis Citizenship Registry and the Matched General Population of Ontario.

![](10.1177_2054358117703071-table1)

                                                                                   Registered Métis   General population   Standardized difference^[a](#table-fn2-2054358117703071){ref-type="table-fn"}^
  -------------------------------------------------------------------------------- ------------------ -------------------- --------------------------------------------------------------------------------
  Demographics                                                                                                             
   Mean age, years (SD)                                                            41.8 (14.7)        41.8 (14.7)          0%
   Median age, years (IQR)                                                         41 (30-51)         41 (30-51)           
   Age category, n (%)                                                                                                     
    18-30                                                                          3247 (26.6%)       12 985 (26.5%)       0%
    31-40                                                                          2601 (21.3%)       10 408 (21.3%)       0%
    41-50                                                                          3106 (25.4%)       12 421 (25.4%)       0%
    51-60                                                                          1833 (15.0%)       7332 (15.0%)         0%
    61-70                                                                          1021 (8.3%)        4086 (8.4%)          0%
    71-80                                                                          361 (3.0%)         1443 (2.9%)          0%
    \>80                                                                           60 (0.5%)          241 (0.5%)           0%
   Women, n (%)                                                                    5627 (46.0%)       22 508 (46.0%)       0%
   Income quintile, n (%)^[b](#table-fn3-2054358117703071){ref-type="table-fn"}^                                           
    1 (lowest)                                                                     2871 (23.5%)       10 520 (21.5%)       5%
    2                                                                              2524 (20.6%)       9779 (20.0%)         2%
    3                                                                              2621 (21.4%)       10 368 (21.2%)       1%
    4                                                                              2209 (18.1%)       9250 (18.9%)         2%
    5 (highest)                                                                    2004 (16.4%)       8999 (18.4%)         5%
   LHIN, n (%)^[c](#table-fn4-2054358117703071){ref-type="table-fn"}^                                                      
    Erie St. Clair                                                                 313 (2.6%)         1251 (2.6%)          0%
    South West                                                                     428 (3.5%)         1672 (3.4%)          0%
    Waterloo Wellington                                                            277 (2.3%)         1129 (2.3%)          0%
    Hamilton Niagara Haldimand Brant                                               673 (5.5%)         2663 (5.4%)          0%
    Central West                                                                   150 (1.2%)         620 (1.3%)           0%
    Mississauga Halton                                                             202 (1.7%)         817 (1.7%)           0%
    Toronto Central                                                                295 (2.4%)         1089 (2.2%)          1%
    Central                                                                        275 (2.2%)         1257 (2.6%)          2%
    Central East                                                                   593 (4.8%)         2421 (4.9%)          1%
    South East                                                                     339 (2.8%)         1368 (2.8%)          0%
    Champlain                                                                      650 (5.3%)         2582 (5.3%)          0%
    North Simcoe Muskoka                                                           2233 (18.3%)       8844 (18.1%)         1%
    North East                                                                     3813 (31.2%)       15 355 (31.4%)       1%
    North West                                                                     1988 (16.3%)       7848 (16.0%)         1%
   Rural status^[d](#table-fn5-2054358117703071){ref-type="table-fn"}^             3719 (30.4%)       14 909 (30.5%)       0%
  Comorbidities, n (%)^[e](#table-fn6-2054358117703071){ref-type="table-fn"}^                                              
   Diabetes                                                                        1067 (8.7%)        3552 (7.3%)          5%
   Myocardial infarction                                                           122 (1.0%)         361 (0.7%)           3%
   Stroke                                                                          55 (0.4%)          175 (0.4%)           2%
  Health care use^[f](#table-fn7-2054358117703071){ref-type="table-fn"}^                                                   
   Previous visit to nephrologist, n (%)                                           61 (0.5%)          234 (0.5%)           0%
   Primary care provider visits                                                                                            
    Mean (SD)                                                                      4.8 (6.2)          3.9 (5.9)            14%
    Median (IQR)                                                                   3 (1-6)            2 (0-5)              
   Previous hospitalizations                                                                                               
    Mean (SD)                                                                      0.1 (0.4)          0.1 (0.4)            3%
    Median (IQR)                                                                   0 (0-0)            0 (0-0)              
     0                                                                             11 404 (93.3%)     45 928 (93.9%)       3%
     1-2                                                                           758 (6.2%)         2757 (5.6%)          2%
     3-4                                                                           58 (0.5%)          188 (0.4%)           1%
     \>5                                                                           9 (0.1%)           43 (0.1%)            1%

*Note.* IQR = interquartile range; LHIN = Local Health Integration Network.

Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups divided by the pooled SD; a value greater than 10% is interpreted as a meaningful difference between groups.

Income was categorized into fifths of average neighborhood income on April 1, 2003.

Those with missing LHINs were entered into the largest LHIN (North East).

Rural was defined as population \< 10 000.

Comorbidities were assessed by administrative database codes in the previous 5 years from April 1, 2003.

Health care use was assessed in the previous 1 year from April 1, 2003.

Chronic Kidney Disease {#section36-2054358117703071}
----------------------

In the year before April 1, 2003, approximately 5% of individuals in our study cohort had at least one laboratory test for serum creatinine (576 Métis citizens and 2304 in the general population) ([Table 2](#table2-2054358117703071){ref-type="table"}). Among these individuals, the baseline prevalence of chronic kidney disease (defined as an eGFR below 60 mL/min/1.73 m^2^) was 6.1% and 4.3%, respectively (relative risk \[RR\], 1.45; 95% confidence interval \[CI\], 1.04-2.02; *P* = 0.03). When stratified by severity of chronic kidney disease, we found similar estimates but these were not statistically significant. The prevalence of chronic kidney disease during follow-up (as defined using validated administrative health care codes in the entire cohort) was 3.1% among Métis citizens and 2.6% in the general population (RR 1.19; 95% CI, 1.07-1.32; *P* = 0.002).

###### 

Prevalence and Severity of Chronic Kidney Disease Among Those With at Least One Serum Creatinine Test in the Year Before April 1, 2003.

![](10.1177_2054358117703071-table2)

                                                                        Registered Métis   General population   Relative risk   95% confidence interval   *P* value
  --------------------------------------------------------------------- ------------------ -------------------- --------------- ------------------------- -----------
  At least one serum creatinine test in the year before April 1, 2003                                                                                     
   Total                                                                n = 576            n = 2304                                                       
   Prevalence of chronic kidney disease, n (%)                          35 (6.1%)          99 (4.3%)            1.45            1.04-2.02                 0.03
  Severity of chronic kidney disease, n (%)                                                                                                               
    Mild (stage 3a): eGFR 45-59 mL/min/17.3 m^2^                        26 (4.5%)          71 (3.1%)            1.52            0.99-2.34                 0.05
    Moderate to severe (stage 3b-5): eGFR below 44 mL/min/1.73 m^2^     9 (1.6%)           28 (1.2%)            1.24            0.61, 2.55                0.55
  At least one validated administrative health care code in follow-up                                                                                     
   Total                                                                n = 12 229         n = 48 916                                                     
   Prevalence of chronic kidney disease, n(%)                           381 (3.1%)         1283 (2.6%)          1.19            1.07-1.32                 0.002

*Note.* eGFR = estimated glomerular filtration rate.

Acute Kidney Injury {#section37-2054358117703071}
-------------------

Similar to the assessment of chronic kidney disease above, approximately 5% of the cohort had baseline serum creatinine values in the year prior to April 1, 2003. When defined using inpatient or emergency department laboratory tests, the incidence of acute kidney injury during follow-up was 1.6 per 1000 person-years among Métis citizens, a rate not statistically different than the 1.2 per 1000 person-years observed in the general population (*P* = 0.89). Similarly, when defined using inpatient diagnosis codes, the incidence of acute kidney injury was not significantly different between groups (1.2 per 1000 person-years among Métis citizens versus 1.2 among the general population; *P* = 0.54).

Outcomes for individuals who were hospitalized with acute kidney injury (defined using diagnostic codes) are shown in [Table 3](#table3-2054358117703071){ref-type="table"}. Most outcomes did not differ between groups, including duration of hospital stay, death during hospitalization, short-term dialysis during hospitalization, and non-recovery of kidney function requiring dialysis. However, death within 1 year of hospital discharge was significantly higher among Métis citizens compared with the general population (26 of 106; 24.5% vs 59 of 386; 15.3%, respectively; *P* = 0.03).

###### 

Outcomes of Individuals Hospitalized With Acute Kidney Injury.^[a](#table-fn10-2054358117703071){ref-type="table-fn"}^

![](10.1177_2054358117703071-table3)

                                                                     Registered Métis                                                     General population                                                   *P* value
  ------------------------------------------------------------------ -------------------------------------------------------------------- -------------------------------------------------------------------- --------------------------------------------------------------
  Hospital length of stay, days                                                                                                                                                                                
   Mean (SD)                                                         13.5 (19.5)                                                          14.4 (19.7)                                                          0.44^[b](#table-fn11-2054358117703071){ref-type="table-fn"}^
   Median (IQR)                                                      7 (4-15)                                                             9 (4-17)                                                             
  Died during hospitalization, n (%)                                 25 (19.1%)                                                           98 (20.2%)                                                           0.77
  Short-term dialysis during hospitalization, n (%)                  8 (6.1%)^[c](#table-fn12-2054358117703071){ref-type="table-fn"}^     33 (6.8%)^[d](#table-fn13-2054358117703071){ref-type="table-fn"}^    0.77
  Died within 1 year of hospital discharge, n (%)                    26 (24.5%)^[c](#table-fn12-2054358117703071){ref-type="table-fn"}^   59 (15.3%)^[d](#table-fn13-2054358117703071){ref-type="table-fn"}^   0.03
  Nonrecovery of kidney function requiring chronic dialysis, n (%)   6 (5.7%)^[c](#table-fn12-2054358117703071){ref-type="table-fn"}^     16 (4.1%)^[d](#table-fn13-2054358117703071){ref-type="table-fn"}^    0.50

*Note.* IQR = interquartile range.

Hospitalization with acute kidney injury, as defined by validated administrative codes.

*P* value based on Wilcoxon signed-rank test for continuous data that are not normally distributed.

Percentage of 106 survivors.

Percentage of 386 survivors.

End-Stage Kidney Disease {#section38-2054358117703071}
------------------------

The incidence of end-stage kidney disease during follow-up was similar between groups: 2.2 per 10 000 person-years among Métis citizens and 2.4 per 10 000 person-years among the general population (*P* = 0.73).

Sensitivity Analyses {#section39-2054358117703071}
--------------------

To examine whether matching on geographic location influenced our results, we removed this criterion in sensitivity analyses, but found no appreciable change in the results (data not shown).

Discussion {#section40-2054358117703071}
==========

This research represents the first population-based study of kidney disease among registered Métis citizens of Ontario. We found that rates of acute kidney injury and end-stage kidney disease were similar for Métis citizens in Ontario and a matched general population sample. However, we did find a slightly higher prevalence of chronic kidney disease among Métis citizens compared with the general population (45% and 19% relative increase when using laboratory values and administrative codes to define chronic kidney disease, respectively). The 45% relative increase should be interpreted with caution, because event rates were small and the CI was wide. Furthermore, the absolute risk differences were small (0.5% when using administrative codes and 1.8% when using laboratory values). The chronic kidney disease prevalence in the general population for our study (2.6% and 4.3% defined by administrative codes and laboratory values, respectively) is consistent with a previous study which estimated chronic kidney disease prevalence in the general population of Canada measured by laboratory values as 3.1%.^[@bibr18-2054358117703071]^

Several previous studies have used Ontario's administrative health care data to examine the prevalence of chronic diseases in registered Métis citizens compared with the general population. These studies found elevated rates of related diseases such as diabetes and cardiovascular disease among Métis citizens, which aligns with our finding of a slightly higher prevalence of chronic kidney disease.^[@bibr19-2054358117703071][@bibr20-2054358117703071]-[@bibr21-2054358117703071]^

These previous studies on rates of diabetes and cardiovascular disease reported age and sex standardized results,^[@bibr19-2054358117703071],[@bibr22-2054358117703071]^ where our findings were based on Métis citizens matched to the general population on age, sex, and area of residence. Importantly, results were unchanged when we removed the matching criterion for area of residence, suggesting that rates of kidney disease are similar between Métis citizens and the age-matched and sex-matched general population in Ontario, regardless of geographic location. This is important because the majority of Métis citizens reside in smaller urban communities in Northern Ontario with potentially less access to health care compared with the general Ontario population.^[@bibr9-2054358117703071]^

In this study, rates of hospitalization with acute kidney injury were similar for Métis citizens and the general population. In a secondary analysis, we found that a significantly higher proportion of Métis citizens died within 1 year of hospital discharge; however, it is important to interpret this result with caution given that this secondary analysis was conducted in a very small subsample of the original cohort (106 Métis and 386 individuals from the general population) and spurious findings can arise in multiple subgroup comparisons. As well, the small number of events meant we were unable to retain the matching on baseline characteristics and so these results could be influenced by between-group differences in age, sex, and area of residence or also by higher comorbidities among Métis citizens, which has been documented in other reports.^[@bibr8-2054358117703071],[@bibr19-2054358117703071],[@bibr21-2054358117703071],[@bibr22-2054358117703071]^ Nonetheless, even if this result could be explained by differences in baseline risk, from a public health perspective, a potentially higher rate of mortality in this subgroup is a cause for concern and requires further investigation, particularly with respect to follow-up care after acute kidney injury. The Acute Kidney Injury Guidelines set by Kidney Disease Improving Global Outcomes (KDIGO)^[@bibr23-2054358117703071]^ recommend that patients diagnosed with acute kidney injury be evaluated 3 months after the episode. While we were not able to examine follow-up care in the present study due to small sample sizes, future investigations should examine the overall quality of care and whether appropriate follow-up care occurs after an episode of acute kidney injury.

Previous research shows that Indigenous people living in Canada have rates of kidney disease that are 2 to 3 times higher compared with the general population.^[@bibr1-2054358117703071],[@bibr24-2054358117703071],[@bibr25-2054358117703071]^ However, when we looked specifically at the Métis population, we found that registered Métis citizens had rates of kidney disease that were similar, or only slightly higher, compared with a matched sample from the general population. The Métis are a distinct Indigenous people, and it is possible that a potentially lower risk among the Métis population may be explained by genetic or environmental factors or by differences in the way health care is provided, for example, via provincial or federal jurisdictions.^[@bibr26-2054358117703071]^ As well, Métis do not live on reserves and are more likely to reside in urban centres,^[@bibr27-2054358117703071]^ which may provide better access to health care. A 2004 CIHI report found that several social and economic indicators of health (including income, employment, and education levels) were lower among First Nations people compared with Métis people.^[@bibr8-2054358117703071]^ The Métis are the fastest growing Indigenous population in Canada, so it is important to continue further investigation of kidney outcomes in this population.^[@bibr9-2054358117703071]^

Limitations {#section41-2054358117703071}
-----------

It is important to consider that the Citizenship Registry of the MNO captures only about 20% of the total Métis population in Ontario and may not be representative of the entire Métis population in Ontario. The registry is populated by individuals who choose to register, and registered citizens may differ from nonregistered citizens on important demographic, behavioral, and clinical factors. For example, some Métis may be motivated to register to gain certain benefits, such as access to harvesting and hunting rights, an activity more likely to be pursued by healthier individuals. These selection biases may have affected our rates of kidney disease, and our estimates may not be generalizable to the wider Métis population residing in Ontario.

Administrative data are widely used for the surveillance of chronic diseases because it is an efficient method to obtain measures on the burden of a disease for an entire population. The health administrative data in Ontario are held at ICES, making them readily available and can be linked to many other databases to create cohorts of the entire Ontario population. However, administrative data have limitations including a lack of comprehensive clinical detail, coding errors, and potential biases related to the method of data collection, such as physician claims data. We have previously shown that the administrative health care codes used to identify kidney disease are highly specific but lack sensitivity.^[@bibr14-2054358117703071],[@bibr16-2054358117703071]^ In other words, there is a low false positive rate, but not all patients with kidney disease will be captured. Specifically, older patients with administrative diagnostic codes for chronic kidney disease had lower eGFR values than individuals without these codes (38 vs 69 mL/min/1.73 m^2^).^[@bibr14-2054358117703071]^ Also, in a previous validation study, we showed that hospitalized patients with a diagnostic code for acute kidney injury had a median increase in serum creatinine of 98 µmol/L (IQR, 43-200) from their prehospitalization baseline value. By contrast, hospitalized patients with no diagnostic code for acute kidney injury had a median serum creatinine increase of 6 µmol/L (IQR, −4-20).^[@bibr16-2054358117703071]^ While we also assessed kidney disease using laboratory tests for serum creatinine, our hospital laboratory data used to assess acute kidney injury incidence are limited to a subsample of individuals who visit a Cerner hospital in Southwestern Ontario (only 5% of the study cohort). With regard to outpatient values used to identify prevalence of chronic kidney disease and baseline values to assess acute kidney injury, we only used laboratory data from Dynacare, which is 1 of the 3 largest outpatient laboratories in Ontario. Since the laboratory data is not available for all of Ontario, it is underestimating the true burden of acute kidney injury and chronic kidney disease in both populations. We are in the process of acquiring the Ontario Laboratories Information System (OLIS) database, which will have all outpatient laboratory tests completed in Ontario, including proteinuria data. We plan to conduct further analyses on this cohort once OLIS becomes available to use. Another important limitation of both administrative and laboratory data is that it only captures those who have accessed the health care system. This is an important issue for studies of the Métis population since we know from other studies that Métis citizens are less likely to access physician and/or specialist services compared with the non-Aboriginal population, suggesting a significant potential for both underdiagnosis and undertreatment of chronic disease relative to the general population in Ontario.^[@bibr28-2054358117703071]^ While it is possible that access may be different between the Métis and general population in our study, it is not likely since the baseline health care use of these 2 groups was similar. Finally, as we cannot identify nonregistered Métis citizens in our data sets, these individuals may have been included in our matched general population sample.

Conclusions {#section42-2054358117703071}
===========

In this 10-year study of kidney disease among registered Métis citizens and a matched sample from the general Ontario population, we found a slightly higher prevalence of chronic kidney disease and similar incidence rates of acute kidney injury and end-stage kidney disease. Although these results are reassuring, further research is needed to replicate findings and inform practice.
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Checklist of Recommendations for Reporting of Observational Studies Using the REporting of Studies Conducted Using Observational Routinely-Collected Health Data (RECORD) Statement.^[@bibr12-2054358117703071]^
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  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                               Item number   STROBE items                                                                                                                                                                                                        RECORD items                                                                                                                                                                                                                                                                                          Reported
  ------------------------------------------------------------ ------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Title and abstract                                           1             \(a\) Indicate the study's design with a commonly used term in the title or the abstract.\                                                                                                                          (1.1) The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included.\                                                                                                                                                          Abstract
                                                                             (b) Provide in the abstract an informative and balanced summary of what was done and what was found.                                                                                                                (1.2) If applicable, the geographic region and time frame within which the study took place should be reported in the title or abstract.\                                                                                                                                                             
                                                                                                                                                                                                                                                                                                 (1.3) If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.                                                                                                                                                                               

  Introduction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

   Background/rationale                                        2             Explain the scientific background and rationale for the investigation being reported.                                                                                                                                                                                                                                                                                                                                                                                                                                     Background

   Objectives                                                  3             State specific objectives, including any prespecified hypotheses.                                                                                                                                                                                                                                                                                                                                                                                                                                                         Background

  Methods                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

   Study design                                                4             Present key elements of study design early in the article.                                                                                                                                                                                                                                                                                                                                                                                                                                                                Methods---Design and Setting

   Setting                                                     5             Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection.                                                                                                                                                                                                                                                                                                                                                                                          Methods

   Participants                                                6             \(a\) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up.\                                                                                      (6.1) The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.\                                                                                                      Methods---Chronic Kidney Disease, Acute Kidney Injury, End-Stage Kidney Disease, [Figure 1](#fig1-2054358117703071){ref-type="fig"}, [Appendix B](#app2-2054358117703071){ref-type="app"}
                                                                             (b) For matched studies, give matching criteria and number of exposed and unexposed.                                                                                                                                (6.2) Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.\                                                                 

                                                                                                                                                                                                                                                                                                 (6.3) If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.                                                                              

   Variables                                                   7             Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.                                                                           (7.1) A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided.                                                                                             Methods---Chronic Kidney Disease, Acute Kidney Injury, End-Stage Kidney Disease, [Appendix B](#app2-2054358117703071){ref-type="app"}

   Data sources/measurement                                    8             For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group.                                                                                                                                                                                                                                                                                                                                     Methods---Data Sources, Chronic Kidney Disease, Acute Kidney Injury, End-Stage Kidney Disease

   Bias                                                        9             Describe any efforts to address potential sources of bias.                                                                                                                                                                                                                                                                                                                                                                                                                                                                Methods---Cohort Selection

   Study size                                                  10            Explain how the study size was arrived at.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                [Figure 1](#fig1-2054358117703071){ref-type="fig"}

   Quantitative variables                                      11            Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why.                                                                                                                                                                                                                                                                                                                                                                                             Methods---Baseline Characteristics, [Table 1](#table1-2054358117703071){ref-type="table"}

   Statistical methods                                         12            \(a\) Describe all statistical methods, including those used to control for confounding.\                                                                                                                                                                                                                                                                                                                                                                                                                                 Statistical Analysis
                                                                             (b) Describe any methods used to examine subgroups and interactions.\                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                             (c) Explain how missing data were addressed.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                             (d) If applicable, explain how loss to follow-up was addressed.\                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                             (e) Describe any sensitivity analyses.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

   Data access and cleaning methods                                          N/A                                                                                                                                                                                                                 (12.1) Authors should describe the extent to which the investigators had access to the database population used to create the study population.\                                                                                                                                                      [Figure 1](#fig1-2054358117703071){ref-type="fig"}
                                                                                                                                                                                                                                                                                                 (12.2) Authors should provide information on the data cleaning methods used in the study.                                                                                                                                                                                                             

   Linkage                                                                   N/A                                                                                                                                                                                                                 (12.3) State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.                                                                                   Methods---Data Sources

  Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

   Participants                                                13            \(a\) Report numbers of individuals at each stage of study---for example, numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed.\   (13.1) Describe in detail the selection of the persons included in the study (ie, study population selection), including filtering based on data quality, data availability, and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.   [Figure 1](#fig1-2054358117703071){ref-type="fig"}, Results
                                                                             (b) Give reasons for nonparticipation at each stage.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                             (c) Consider use of a flow diagram.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

   Descriptive data                                            14            \(a\) Give characteristics of study participants (eg, demographic, clinical, social) and information on exposures and potential confounders.\                                                                                                                                                                                                                                                                                                                                                                             Results---Baseline Characteristics, Chronic Kidney Disease, Acute Kidney Injury, End-Stage Kidney Disease, [Table 1](#table1-2054358117703071){ref-type="table"}
                                                                             (b) Indicate number of participants with missing data for each variable of interest.\                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                             (c) Summarize follow-up time (eg, average and total amount).                                                                                                                                                                                                                                                                                                                                                                                                                                                              

   Outcome data                                                15            Report numbers of outcome events or summary measures over time.                                                                                                                                                                                                                                                                                                                                                                                                                                                           Results---Chronic Kidney Disease, Acute Kidney Injury, End-Stage Kidney Disease, [Tables 2](#table2-2054358117703071){ref-type="table"}, [3](#table3-2054358117703071){ref-type="table"}

   Main results                                                16            \(a\) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included.\                                                                                                                                                                                                                                                                                                          Results, [Tables 2](#table2-2054358117703071){ref-type="table"}, [3](#table3-2054358117703071){ref-type="table"}
                                                                             (b) Report category boundaries when continuous variables were categorized.\                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                             (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period.                                                                                                                                                                                                                                                                                                                                                                                                         

   Other analyses                                              17            Report other analyses done (eg, analyses of subgroups and interactions, and sensitivity analyses).                                                                                                                                                                                                                                                                                                                                                                                                                        Sensitivity Analyses

   Key results                                                 18            Summarize key results with reference to study objectives.                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Discussion

   Limitations                                                 19            Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.                                                         (19.1) Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.    Discussion---Limitations

  Interpretation                                               20            Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.                                                                                                                                                                                                                                                                                                                                               Discussion

   Generalizability                                            21            Discuss the generalizability (external validity) of the study results.                                                                                                                                                                                                                                                                                                                                                                                                                                                    Conclusion

  Other information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

   Funding                                                     22            Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based.                                                                                                                                                                                                                                                                                                                                                            Acknowledgments

   Accessibility of protocol, raw data, and programming code                 N/A                                                                                                                                                                                                                 (22.1) Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.                                                                                                                                                    N/A
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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Administrative Health Care Codes Used to Define Kidney Disease.
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  Kidney Disease Type                                                              Source                                                                                                                                                                                                                                                  Code                                                                                                                   Description
  -------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------
  Chronic Kidney Disease^[a](#table-fn15-2054358117703071){ref-type="table-fn"}^   Defined as evidence of at least one of the chronic kidney disease validated administrative diagnostic codes during the follow-up period                                                                                                                                                                                                                                        
                                                                                   CIHI-DAD^[b](#table-fn16-2054358117703071){ref-type="table-fn"}^                                                                                                                                                                                        E102                                                                                                                   Type 1 diabetes mellitus with incipient diabetic nephropathy adequately or inadequately controlled with insulin, diet, oral agents
                                                                                                                                                                                                                                                                                                                                           E112                                                                                                                   Type 2 diabetes mellitus with incipient diabetic nephropathy adequately or inadequately controlled with insulin, diet, oral agents
                                                                                                                                                                                                                                                                                                                                           E132                                                                                                                   Other specified diabetes mellitus with incipient diabetic nephropathy adequately or inadequately controlled with insulin, diet, oral agents
                                                                                                                                                                                                                                                                                                                                           E142                                                                                                                   Unspecified diabetes mellitus with incipient diabetic nephropathy adequately or inadequately controlled with insulin, diet, oral agents
                                                                                                                                                                                                                                                                                                                                           I12                                                                                                                    Hypertensive renal disease
                                                                                                                                                                                                                                                                                                                                           I13                                                                                                                    Hypertensive renal and heart disease
                                                                                                                                                                                                                                                                                                                                           N08                                                                                                                    Glomerular disorders in diseases classified elsewhere
                                                                                                                                                                                                                                                                                                                                           N18                                                                                                                    Chronic renal failure
                                                                                                                                                                                                                                                                                                                                           N19                                                                                                                    Unspecified renal failure
                                                                                   OHIP diagnosis code                                                                                                                                                                                                                                     403                                                                                                                    Hypertensive renal disease
                                                                                                                                                                                                                                                                                                                                           585                                                                                                                    Chronic renal failure, uremia
  Acute Kidney Injury^[a](#table-fn15-2054358117703071){ref-type="table-fn"}^      Defined as evidence of the acute kidney injury validated administrative diagnostic code during the follow-up period                                                                                                                                                                                                                                                            
                                                                                   CIHI-DAD^[b](#table-fn16-2054358117703071){ref-type="table-fn"}^                                                                                                                                                                                        N17                                                                                                                    Acute renal failure
  End-Stage Kidney Disease                                                         End-stage kidney disease defined as evidence of at least one treatment code for chronic dialysis (hemodialysis or peritoneal dialysis) or kidney transplantation during the follow-up period                                                                                                                                                                                   
  End-Stage Kidney Disease - Dialysis                                              CORR Treatment Code                                                                                                                                                                                                                                     111                                                                                                                    1: Acute Care Hospital, 1: Conventional Hemodialysis, 1: Total Care
                                                                                                                                                                                                                                                                                                                                           112                                                                                                                    1: Acute Care Hospital, 1: Conventional Hemodialysis, 2: Limited Self-Care
                                                                                                                                                                                                                                                                                                                                           113                                                                                                                    1: Acute Care Hospital, 1: Conventional Hemodialysis, 3: Total Self-Care
                                                                                                                                                                                                                                                                                                                                           121                                                                                                                    1: Acute Care Hospital, 2: Short Daily Hemodialysis, 1: Total Care
                                                                                                                                                                                                                                                                                                                                           122                                                                                                                    1: Acute Care Hospital, 2: Short Daily Hemodialysis, 2: Limited Self-Care
                                                                                                                                                                                                                                                                                                                                           123                                                                                                                    1: Acute Care Hospital, 2: Short Daily Hemodialysis, 3: Total Self-Care
                                                                                                                                                                                                                                                                                                                                           131                                                                                                                    1: Acute Care Hospital, 3: Slow Nocturnal Hemodialysis, 1: Total Care
                                                                                                                                                                                                                                                                                                                                           132                                                                                                                    1: Acute Care Hospital, 3: Slow Nocturnal Hemodialysis, 2: Limited Self-Care
                                                                                                                                                                                                                                                                                                                                           133                                                                                                                    1: Acute Care Hospital, 3: Slow Nocturnal Hemodialysis, 3: Total Self-Care
                                                                                                                                                                                                                                                                                                                                           211                                                                                                                    2: Chronic Care Hospital, 1: Conventional Hemodialysis, 1: Total Care
                                                                                                                                                                                                                                                                                                                                           221                                                                                                                    2: Chronic Care Hospital, 2: Short Daily Hemodialysis, 1: Total Care
                                                                                                                                                                                                                                                                                                                                           231                                                                                                                    2: Chronic Care Hospital, 3: Slow Nocturnal Hemodialysis, 1: Total Care
                                                                                                                                                                                                                                                                                                                                           311                                                                                                                    3: Community Centre, 1: Conventional Hemodialysis, 1: Total Care
                                                                                                                                                                                                                                                                                                                                           312                                                                                                                    3: Community Centre, 1: Conventional Hemodialysis, 2: Limited Self-Care
                                                                                                                                                                                                                                                                                                                                           313                                                                                                                    3: Community Centre, 1: Conventional Hemodialysis, 3: Total Self-Care
                                                                                                                                                                                                                                                                                                                                           321                                                                                                                    3: Community Centre, 2: Short Daily Hemodialysis, 1: Total Care
                                                                                                                                                                                                                                                                                                                                           322                                                                                                                    3: Community Centre, 2: Short Daily Hemodialysis, 2: Limited Self-Care
                                                                                                                                                                                                                                                                                                                                           323                                                                                                                    3: Community Centre, 2: Short Daily Hemodialysis, 3: Total Self-Care
                                                                                                                                                                                                                                                                                                                                           331                                                                                                                    3: Community Centre, 3: Slow Nocturnal Hemodialysis, 1: Total Care
                                                                                                                                                                                                                                                                                                                                           332                                                                                                                    3: Community Centre, 3: Slow Nocturnal Hemodialysis, 2: Limited Self-Care
                                                                                                                                                                                                                                                                                                                                           333                                                                                                                    3: Community Centre, 3: Slow Nocturnal Hemodialysis, 3: Total Self-Care
                                                                                                                                                                                                                                                                                                                                           413                                                                                                                    4: Home, 1: Conventional Hemodialysis, 3: Total Self-Care
                                                                                                                                                                                                                                                                                                                                           423                                                                                                                    4: Home, 2: Short Daily Hemodialysis, 3: Total Self-Care
                                                                                                                                                                                                                                                                                                                                           433                                                                                                                    4: Home, 3: Slow Nocturnal Hemodialysis, 3: Total Self-Care
                                                                                                                                                                                                                                                                                                                                           141                                                                                                                    1: Acute Care Hospital, 4: CAPD, 1: Total Care
                                                                                                                                                                                                                                                                                                                                           151                                                                                                                    1: Acute Care Hospital, 5: APD, 1: Total Care
                                                                                                                                                                                                                                                                                                                                           152                                                                                                                    1: Acute Care Hospital, 5: APD, 2: Limited Self-Care
                                                                                                                                                                                                                                                                                                                                           241                                                                                                                    2: Chronic Care Hospital, 4: CAPD, 1: Total Care
                                                                                                                                                                                                                                                                                                                                           242                                                                                                                    2: Chronic Care Hospital, 4: CAPD, 2: Limited Self-Care
                                                                                                                                                                                                                                                                                                                                           252                                                                                                                    2: Chronic Care Hospital, 5: APD, 2: Limited Self-Care
                                                                                                                                                                                                                                                                                                                                           443                                                                                                                    4: Home, 4: CAPD, 3: Total Self-Care
                                                                                                                                                                                                                                                                                                                                           453                                                                                                                    4: Home, 5: APD, 3: Total Self-Care
  End-Stage Kidney Disease---Kidney Transplant                                     For evidence of Kidney Transplant; must have the CORR Treatment Code with at least one CORR Transplant Organ Type Code.                                                                                                                                                                                                                                                        
  CORR Treatment Code                                                              1711011                                                                                                                                                                                                                                                 1: Acute Care Hospital, 7: Transplantation, 1: Total CareKidneys/dialysis (includes en bloc transplants)Kidney: Left   
  CORR Transplant Organ Type Code                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                           12                                                                                                                     Kidney: Right
                                                                                                                                                                                                                                                                                                                                           18                                                                                                                     Kidney: One (from conversion)
                                                                                                                                                                                                                                                                                                                                           19                                                                                                                     Kidney: Two (from conversion)
  Non-recovery of acute kidney injury resulting in chronic dialysis                Non-recovery of kidney function and dialysis dependence at 90 days from the date of hospital discharge from acute kidney injury event. This is defined as at least one code of the following between day 76 and Day 104 from hospital discharge date.                                                                                                                          
                                                                                   OHIP Fee code                                                                                                                                                                                                                                           R849                                                                                                                   Dialysis: Hemodialysis---initial and acute
                                                                                                                                                                                                                                                                                                                                           R850                                                                                                                   Dialysis: Hemodialysis---insert of Scribner shunt
                                                                                                                                                                                                                                                                                                                                           G323                                                                                                                   Dialysis: Hemodialysis---acute, repeat (maximum 3)
                                                                                                                                                                                                                                                                                                                                           G325                                                                                                                   Dialysis: Hemodialysis---medical component (including in unit fee)
                                                                                                                                                                                                                                                                                                                                           G326                                                                                                                   Dialysis: Chronic, continuous hemodialysis or hemofiltration
                                                                                                                                                                                                                                                                                                                                           G330                                                                                                                   Peritoneal dialysis---acute (up to 48 h)
                                                                                                                                                                                                                                                                                                                                           G331                                                                                                                   Peritoneal dialysis---repeat, acute (up to 48 h) maximum 3
                                                                                                                                                                                                                                                                                                                                           G332                                                                                                                   Peritoneal dialysis---chronic (up to 48 h)
                                                                                                                                                                                                                                                                                                                                           G860                                                                                                                   Chronic hemodialysis hospital location
                                                                                                                                                                                                                                                                                                                                           G333                                                                                                                   Home/self-care dialysis
                                                                                                                                                                                                                                                                                                                                           G083                                                                                                                   Continuous venovenous hemodialysis
                                                                                                                                                                                                                                                                                                                                           G091                                                                                                                   Continuous arteriovenous hemodialysis
                                                                                                                                                                                                                                                                                                                                           G085                                                                                                                   Continuous venovenous hemofiltration
                                                                                                                                                                                                                                                                                                                                           G295                                                                                                                   Continuous aterivenous hemofiltration initial and acute
                                                                                                                                                                                                                                                                                                                                           G082                                                                                                                   Continuous venovenous hemodialfiltration
                                                                                                                                                                                                                                                                                                                                           G090                                                                                                                   Veneovenous slow continuous ultrafiltration
                                                                                                                                                                                                                                                                                                                                           G092                                                                                                                   Continuous arteriovenous hemodiafiltration
                                                                                                                                                                                                                                                                                                                                           G093                                                                                                                   Hemodiafiltration: Continuous initial and acute (repeatx3)
                                                                                                                                                                                                                                                                                                                                           G094                                                                                                                   Hemodiafiltration: Continuous Chronic
                                                                                                                                                                                                                                                                                                                                           G861                                                                                                                   Chronic peritoneal dialysis hospital location
                                                                                                                                                                                                                                                                                                                                           G862                                                                                                                   Hospital self-care Chronic hemodialysis
                                                                                                                                                                                                                                                                                                                                           G863                                                                                                                   Chronic hemodialysis IHF location
                                                                                                                                                                                                                                                                                                                                           G864                                                                                                                   Chronic Home peritoneal dialysis
                                                                                                                                                                                                                                                                                                                                           G865                                                                                                                   Chronic Home hemodialysis
                                                                                                                                                                                                                                                                                                                                           G866                                                                                                                   Intermittent hemodialysis treatment center
                                                                                                                                                                                                                                                                                                                                           G294                                                                                                                   Arteriovenous slow continuous ultrafiltration init and acute
                                                                                                                                                                                                                                                                                                                                           G095                                                                                                                   Slow Continuous Ultra Filtration: initial and acute (repeat)
                                                                                                                                                                                                                                                                                                                                           G096                                                                                                                   Slow Continuous Ultra Filtration: Chronic
  Acute kidney injury requiring short-term dialysis                                During hospitalization with acute kidney injury, evidence of at least one acute dialysis code.                                                                                                                                                                                                                                                                                 
  OHIP Fee code                                                                    R849                                                                                                                                                                                                                                                    Dialysis: Hemodialysis---initial and acute                                                                             
                                                                                   G323                                                                                                                                                                                                                                                    Dialysis: Hemodialysis---acute, repeat (maximum 3)                                                                     
                                                                                                                                                                                                                                                                                                                                           G866                                                                                                                   Intermittent hemodialysis treatment center
                                                                                                                                                                                                                                                                                                                                           G330                                                                                                                   Peritoneal dialysis---acute (up to 48 h)
                                                                                                                                                                                                                                                                                                                                           G331                                                                                                                   Peritoneal dialysis---repeat acute (up to 48 h) maximum 3
                                                                                                                                                                                                                                                                                                                                           G093                                                                                                                   Hemodiafiltration---continuous initial and acute (repeatx3)
                                                                                                                                                                                                                                                                                                                                           G095                                                                                                                   Slow Continuous Ultra Filtration---initial and acute (repeat)
                                                                                                                                                                                                                                                                                                                                           G294                                                                                                                   Arteriovenous slow continuous ultrafiltration initial and acute
                                                                                                                                                                                                                                                                                                                                           G295                                                                                                                   Continuous aterivenous hemofiltration initial and acute

*Note.* CIHI-DAD = Canadian Institute for Health Information's Discharge Abstract Database; OHIP = Ontario Health Insurance Plan; CORR = Canadian Organ Replacement Register; ICD-10 = International Classifications of Diseases, 10th revision.

Chronic kidney disease and acute kidney injury codes have been validated. See the studies of Fleet et al^[@bibr14-2054358117703071]^ and Hwang et al.^[@bibr16-2054358117703071]^

ICD-10 code type was used.
